Invuity revenue was $39.62 m in FY, 2017 which is a 22.1% year over year increase from the previous period.

## Founding Date | 2004 |

## Total Funding | $180.6 m |

## Investors | Kleiner Perkins, InterWest Partners, HealthCare Royalty Partners, Valence Life Sciences, Wexford Capital |

In total, Invuity had raised $180.6 m. Invuity is a subsidiary of Stryker

USD | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|

## Revenue | 21.0m | 32.5m | 39.6m |

| 54% | 22% | |

## Cost of goods sold | 7.7m | 8.8m | 11.7m |

## Gross profit | 13.3m | 23.6m | 27.9m |

| 63% | 73% | 70% |

## R&D expense | 7.9m | 9.9m | 9.0m |

## General and administrative expense | 40.6m | 52.4m | 54.1m |

## Operating expense total | 48.5m | 62.3m | 63.1m |

## EBIT | (35.2m) | (38.7m) | (35.3m) |

| (167%) | (119%) | (89%) |

## Interest expense | 1.9m | 2.0m | 2.4m |

## Interest income | 482.0k | 89.0k | 222.0k |

## Net Income | (37.6m) | (40.6m) | (39.9m) |

- Source: SEC Filings

USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 4.7m | 5.6m | 6.4m | 8.2m | 8.5m | 9.0m | 9.8m | 9.6m | 9.5m | 10.5m |

## Cost of goods sold | 1.9m | 2.0m | 2.1m | 2.1m | 2.2m | 2.1m | 3.0m | 2.9m | 2.9m | 4.1m |

## Gross profit | 2.8m | 3.6m | 4.3m | 6.1m | 6.3m | 6.9m | 6.8m | 6.7m | 6.6m | 6.4m |

| 59% | 64% | 67% | 75% | 74% | 77% | 69% | 70% | 69% | 61% |

## R&D expense | 1.9m | 2.0m | 2.6m | 2.3m | 2.5m | 2.4m | 2.4m | 2.3m | 1.9m | 2.1m |

## General and administrative expense | 9.8m | 10.2m | 13.3m | 13.4m | 12.1m | 14.9m | 14.2m | 12.8m | 15.1m | 12.5m |

## Operating expense total | 11.7m | 12.2m | 15.9m | 15.8m | 14.6m | 17.3m | 16.6m | 15.1m | 17.0m | 14.6m |

## EBIT | (8.9m) | (8.7m) | (11.6m) | (9.6m) | (8.3m) | (10.4m) | (9.9m) | (8.4m) | (10.4m) | (8.2m) |

| (187%) | (155%) | (181%) | (117%) | (98%) | (115%) | (101%) | (88%) | (110%) | (78%) |

## Interest expense | 504.0k | 504.0k | 505.0k | 505.0k | 505.0k | 487.0k | 527.0k | 545.0k | 775.0k | 794.0k |

## Interest income | 24.0k | 28.0k | 18.0k | 13.0k | 30.0k | 57.0k | 53.0k | 51.0k | 56.0k | 109.0k |

- Source: SEC Filings

USD | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|

## Cash | 46.3m | 28.3m | 18.0m |

## Accounts Receivable | 3.6m | 5.8m | 7.4m |

## Prepaid Expenses | 1.3m | ||

## Inventories | 923.0k | 1.1m | 7.4m |

## Current Assets | 56.0m | 51.1m | 37.3m |

## PP&E | 9.2m | 8.3m | 7.2m |

## Total Assets | 66.3m | 60.3m | 45.5m |

## Accounts Payable | 2.5m | 2.2m | 3.6m |

## Short-term debt | 1.4m | 5.9m | |

## Current Liabilities | 6.7m | 9.9m | 14.6m |

## Long-term debt | 14.5m | 13.3m | 29.1m |

## Total Debt | 14.5m | 14.6m | 29.1m |

## Total Liabilities | 25.9m | 46.4m | |

## Common Stock | 17.0k | ||

## Additional Paid-in Capital | 147.9m | 180.6m | 185.3m |

## Retained Earnings | (105.6m) | (146.2m) | (186.1m) |

## Total Equity | 42.3m | 34.4m | (862.0k) |

## Debt to Equity Ratio | 0.3 x | 0.4 x | -33.8 x |

## Debt to Assets Ratio | 0.2 x | 0.2 x | 0.6 x |

## Financial Leverage | 1.6 x | 1.8 x | -52.8 x |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|

## Net Income | (37.6m) | (40.6m) | (39.9m) |

## Depreciation and Amortization | 1.7m | 2.0m | 2.0m |

## Accounts Receivable | (1.0m) | (2.3m) | (1.6m) |

## Inventories | 1.6m | 130.0k | (2.4m) |

## Accounts Payable | 1.3m | (284.0k) | 1.4m |

## Cash From Operating Activities | (31.2m) | (36.6m) | (38.9m) |

## Purchases of PP&E | (3.7m) | (1.0m) | (844.0k) |

## Cash From Investing Activities | (3.7m) | (11.8m) | 6.9m |

## Long-term Borrowings | (2.5m) | ||

## Cash From Financing Activities | 75.1m | 30.4m | 21.5m |

## Net Change in Cash | (10.5m) | ||

## Interest Paid | 275.0k | 1.5m |

- Source: SEC Filings

USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
---|---|---|---|---|---|---|---|---|---|---|

## Net Income | (18.4m) | (27.5m) | (12.1m) | (22.2m) | (31.1m) | (13.2m) | (23.6m) | (32.5m) | (11.2m) | (20.1m) |

## Depreciation and Amortization | 819.0k | 1.3m | 484.0k | 972.0k | 1.5m | 497.0k | 1.0m | 1.5m | 365.0k | 748.0k |

## Accounts Receivable | (528.0k) | (633.0k) | (432.0k) | (877.0k) | (1.6m) | (278.0k) | 262.0k | (443.0k) | 1.3m | 835.0k |

## Inventories | (555.0k) | (611.0k) | (393.0k) | (268.0k) | 61.0k | (861.0k) | (508.0k) | (1.4m) | (1.3m) | (1.1m) |

## Accounts Payable | 131.0k | 30.0k | (650.0k) | (129.0k) | 327.0k | 1.1m | 716.0k | 1.3m | (388.0k) | (131.0k) |

## Cash From Operating Activities | (15.2m) | (23.9m) | (12.2m) | (20.3m) | (28.0m) | (12.8m) | (21.3m) | (31.1m) | (8.5m) | (18.1m) |

## Purchases of PP&E | (2.7m) | (3.2m) | (290.0k) | (496.0k) | (884.0k) | (288.0k) | (558.0k) | (668.0k) | (182.0k) | (413.0k) |

## Cash From Investing Activities | (2.7m) | (3.1m) | (290.0k) | (496.0k) | (884.0k) | 912.0k | 472.0k | 5.6m | (182.0k) | (5.9m) |

## Cash From Financing Activities | 77.6m | 75.0m | 18.0k | (49.0k) | 30.3m | 8.5m | 9.3m | 21.5m | 20.3m | 21.4m |

## Net Change in Cash | 59.7m | 48.0m | (12.4m) | (20.8m) | 1.4m | (3.3m) | (11.5m) | (4.0m) | (2.6m) | |

## Interest Paid | 608.0k | 1.2m |

- Source: SEC Filings

USD | Q2, 2015 |
---|---|

## Financial Leverage | 1.4 x |

Q4, 2015 | Q4, 2016 | FY, 2016 | |
---|---|---|---|

## Customers | 530 | 745 | |

## Facilities | 1 | ||

## Patent Applications | 46 | ||

## Patents Issued | 44 | ||

## Products | 40 | ||

## Trademarks | 38 |

- Source: SEC Filings